Turn Therapeutics Inc. Common Stock TTRX
i
Market datapartial · fetched 2026-11-13T10:49:02.585Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T21:00:00.296306876Z
FundamentalsAlpha Vantage · unavailable
Turn Therapeutics Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 7.03 | 595.4% | 45.7% | |||
| 25Δ | 7.94 | 511.1% | 37.4% | |||
| 30Δ | 8.66 | 451.0% | 31.2% | |||
| 35Δ | 23.47 | 677.2% | 146.3% | 9.38 | 390.9% | 25.0% |
| 40Δ | 16.33 | 525.9% | 75.9% | 10.03 | 335.5% | 19.3% |
| 45Δ | 13.59 | 446.8% | 49.5% | 10.29 | 312.7% | 17.4% |
| 50Δ | 12.03 | 397.9% | 35.2% | 10.55 | 289.9% | 15.5% |
| 55Δ | 11.06 | 366.2% | 27.0% | 10.80 | 267.1% | 13.5% |
| 60Δ | 10.09 | 334.4% | 18.7% | 11.06 | 244.3% | 11.6% |
| 65Δ | 9.61 | 309.5% | 15.4% | 11.31 | 221.5% | 9.7% |
| 70Δ | 9.17 | 285.3% | 12.6% | 11.57 | 198.7% | 7.8% |
| 75Δ | 8.74 | 261.0% | 9.7% | 11.83 | 175.9% | 5.8% |
| 80Δ | 8.30 | 236.8% | 6.9% | 12.08 | 153.1% | 3.9% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.03
- IV
- 595.4%
- B/E move
- 45.7%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.94
- IV
- 511.1%
- B/E move
- 37.4%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.66
- IV
- 451.0%
- B/E move
- 31.2%
35Δ
- Pseudo strike
- 23.47
- IV
- 677.2%
- B/E move
- 146.3%
- Pseudo strike
- 9.38
- IV
- 390.9%
- B/E move
- 25.0%
40Δ
- Pseudo strike
- 16.33
- IV
- 525.9%
- B/E move
- 75.9%
- Pseudo strike
- 10.03
- IV
- 335.5%
- B/E move
- 19.3%
45Δ
- Pseudo strike
- 13.59
- IV
- 446.8%
- B/E move
- 49.5%
- Pseudo strike
- 10.29
- IV
- 312.7%
- B/E move
- 17.4%
50Δ
- Pseudo strike
- 12.03
- IV
- 397.9%
- B/E move
- 35.2%
- Pseudo strike
- 10.55
- IV
- 289.9%
- B/E move
- 15.5%
55Δ
- Pseudo strike
- 11.06
- IV
- 366.2%
- B/E move
- 27.0%
- Pseudo strike
- 10.80
- IV
- 267.1%
- B/E move
- 13.5%
60Δ
- Pseudo strike
- 10.09
- IV
- 334.4%
- B/E move
- 18.7%
- Pseudo strike
- 11.06
- IV
- 244.3%
- B/E move
- 11.6%
65Δ
- Pseudo strike
- 9.61
- IV
- 309.5%
- B/E move
- 15.4%
- Pseudo strike
- 11.31
- IV
- 221.5%
- B/E move
- 9.7%
70Δ
- Pseudo strike
- 9.17
- IV
- 285.3%
- B/E move
- 12.6%
- Pseudo strike
- 11.57
- IV
- 198.7%
- B/E move
- 7.8%
75Δ
- Pseudo strike
- 8.74
- IV
- 261.0%
- B/E move
- 9.7%
- Pseudo strike
- 11.83
- IV
- 175.9%
- B/E move
- 5.8%
80Δ
- Pseudo strike
- 8.30
- IV
- 236.8%
- B/E move
- 6.9%
- Pseudo strike
- 12.08
- IV
- 153.1%
- B/E move
- 3.9%
Options history
Table
| Date | IV (%) |
|---|---|
| 150.21% | |
| 152.37% | |
| 172.09% | |
| 173.87% | |
| 169.22% | |
| 177.08% | |
| 177.31% | |
| 168.05% | |
| 173.92% | |
| 183.36% |
Biotechnology
TVTX
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development and commercialization of therapies for the treatment of rare diseases. The…
More →TWST
Description unavailable
More →TYRA
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and improve outcomes for cancer patients. The…
More →UNCY
Unicycive Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on pioneering therapies for kidney diseases, particularly in the management of hyperphosphatemia.…
More →UPB
Description unavailable
More →URGN
UroGen Pharma Ltd (URGN) is an innovative biotechnology company focused on the development of advanced therapies for urological diseases, including urothelial carcinoma and…
More →